A Russian vaccine against birch pollen allergy is expected to become available in the second half of 2026, Dmitry Kudlay, Vice President of Generium, the pharmaceutical developer, told TASS.
This is a recombinant vaccine for the treatment of seasonal pollinosis caused by antigens such as birch pollen, with cross-reactivity to stone fruits and related plants. To date, regulatory approval has been granted for the next phase of clinical trials. The process will take approximately six months,” Kudlay stated, adding that the drug is expected to enter the healthcare system in the second half of next year.
Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), previously stated that the drug is expected to be registered by the end of 2025, with approximately a year and a half needed to incorporate it into medical practice.
First reports on the creation of a birch pollen allergy vaccine appeared in 2023. It was developed by scientists from the Institute of Immunology of the FMBA together with colleagues from the Vienna Medical University. Upon completion of the tests, the drug can be included in the National Vaccination Calendar. It is anticipated that only three to five injections will be sufficient to eliminate an allergic reaction, compared to the current treatments that may require up to 30 injections.